NCT04108962 is a Phase 4 clinical trial of Fasenra, 30 Mg/mL Subcutaneous Solution in ABPA, sponsored by Baylor Research Institute.

Who is sponsoring NCT04108962?

NCT04108962 is sponsored by Baylor Research Institute.

What drugs are being tested in NCT04108962?

Interventions in NCT04108962: Fasenra, 30 Mg/mL Subcutaneous Solution.

What condition does NCT04108962 study?

NCT04108962 studies ABPA, Severe Asthma, Allergic Bronchopulmonary Aspergillosis.

Is NCT04108962 still recruiting?

NCT04108962 is currently withdrawn. Last updated 1 February 2022.

Last reviewed 2022-02-01 · How we verify

NCT04108962

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Benralizumab in the Treatment of Patients With Severe Asthma With ABPA

Withdrawn Phase 4 Last updated 1 February 2022

What this trial tests

Phase 4 trial testing Fasenra, 30 Mg/mL Subcutaneous Solution in ABPA. Withdrawn.

Timeline

23 December 2019

Primary endpoint
24 September 2021

1 October 2021

Quick facts

Lead sponsor	Baylor Research Institute
Phase	Phase 4
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	23 December 2019
Primary completion	24 September 2021
Estimated completion	1 October 2021
Sites	1 location across United States

Drugs / interventions tested

Fasenra, 30 Mg/mL Subcutaneous Solution — full drug profile →

Conditions studied

ABPA — all drugs for ABPA →
Severe Asthma — all drugs for Severe Asthma →
Allergic Bronchopulmonary Aspergillosis — all drugs for Allergic Bronchopulmonary Aspergillosis →

Sponsor

Baylor Research Institute

Who can join

Adults 18 to 75, any sex, with ABPA or Severe Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase IV, open-label study will evaluate effects of Benralizumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Therapeutic Antibodies for the Treatment of Respiratory Tract Infections-Current Overview and Perspectives.
Mayor A, Chesnay A, Desoubeaux G, Ternant D, et al · · 2021 · cited 9× · PMID 33668613 · DOI 10.3390/vaccines9020151
The Role of Benralizumab in Eosinophilic Immune Dysfunctions: A Case Report-Based Literature Review.
Gomes M, Mendes A, Ferreira F, Branco J, et al · · 2023 · cited 3× · PMID 37138643 · DOI 10.1155/2023/8832242
Advances of Drug-Loaded Microsphere Technology for Targeted Immunotherapy Against Prostate Cancer.
Feng W. · · 2025 · PMID 41001103 · DOI 10.2147/ijn.s526247

Verify or expand the search:

Other recruiting trials for ABPA

Currently open trials in the same condition.

NCT07362667 — A Study of the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With ABPA · recruiting
NCT07530770 — Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis · recruiting
NCT07313904 — Effects of Environmental Fungal Exposure on Bronchial Asthma, ABPA and Bronchiectasis · recruiting
NCT07362693 — A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA · recruiting

Other Baylor Research Institute trials

Trials by the same sponsor.

NCT07467720 — Study to Evaluate the Clinical Utility of Radiation Exposure Reduction: Multi-site Rampart Guardian Peripheral Trial · NA · not yet recruiting
NCT07547878 — Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) · Phase 4 · not yet recruiting
NCT07460583 — ProActive Athlete Heart Program: Proposal for Cardiac Risk Screening in Former High-Intensity Athletes · NA · not yet recruiting
NCT07096544 — CALM Study: Cardiomems Assisted Lvad Management · NA · not yet recruiting
NCT07220395 — eHealth Literacy Intervention for Spanish Speaking Older Adults in the US · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04108962 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Baylor Research Institute
Last refreshed: 1 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04108962.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing